Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
about
Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic PropertiesNovel antifungal agents: a patent review (2013 - present).In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasisSafety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.The antifungal pipeline: a reality check.Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.Drugs in Clinical Development for Fungal Infections.Antifungal resistance: current trends and future strategies to combat.Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive Candidiasis Murine Model Using an Extended Interval Dosing Design.Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.Biofilms and beyond: expanding echinocandin utility.Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.An introduction to the future of echinocandin therapy.Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.Recent Insights into the Paradoxical Effect of Echinocandins.CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms.Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.
P2860
Q28817906-A6FBB57B-FC46-4E17-853C-D975951D5C3BQ30239745-348ED5BC-7549-41EF-9950-CECE77EE553AQ33589734-6BB047A5-E847-4C27-9926-D0B431602B40Q37612980-C035E55C-80C3-4F81-B5B3-6CA16897A51CQ37669855-EEBD484F-9A4F-49F8-999A-49FF0DC5088CQ37720796-F46DC1E8-7C15-402B-9949-F25052F968DDQ38605120-1957A71B-CAA9-49B2-A7E7-2CC839E80BB5Q39299949-4BCAFD1F-E64F-4DCE-B581-E8EB85268D2AQ40045666-05F34FF3-118C-4B40-B08A-571AE33125DAQ40070714-45BBDB65-19B4-48AA-99C1-2047EABA1205Q41632930-8D695BD8-BA4A-4F81-9800-B364A76B6F19Q46248423-4B5ED338-C890-4AFC-BC9E-A46DE32E4E4EQ46250284-236C7B4B-E706-41A9-81BD-9DD317182401Q47205366-576FFCB4-DD0B-4AB9-95E4-D1FBC071072BQ47205373-4A98A262-2332-4276-AC75-144A7E139F81Q47749829-4531E43A-7817-4B56-8A5D-4E9ADEA88E83Q47749857-B8C77B42-0115-430E-A4E1-00A06D43BC7EQ49390751-ECE5168A-155B-4CC4-BB83-B69F01FF5A26Q49679966-5219E4AA-E356-44B5-96B3-794EDF484CFFQ50042600-019DFAAC-609A-47E0-A54F-7E0DF1FD2B03Q52648077-A4C88C00-D949-4DC2-9A74-7D8A61AC3FFEQ53692883-ED2B847B-8E1A-4BCF-8BCE-0B60A767A552Q55098668-CC4C6596-E229-4333-BBE8-E7A888AA4F29
P2860
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activity of a long-acting echi ...... and azole-resistant isolates.
@en
Activity of a long-acting echi ...... and azole-resistant isolates.
@nl
type
label
Activity of a long-acting echi ...... and azole-resistant isolates.
@en
Activity of a long-acting echi ...... and azole-resistant isolates.
@nl
prefLabel
Activity of a long-acting echi ...... and azole-resistant isolates.
@en
Activity of a long-acting echi ...... and azole-resistant isolates.
@nl
P2093
P2860
P356
P1476
Activity of a long-acting echi ...... and azole-resistant isolates.
@en
P2093
Paul R Rhomberg
Ronald N Jones
Shawn A Messer
P2860
P304
P356
10.1093/JAC/DKW214
P407
P577
2016-06-10T00:00:00Z